This article reported on the clinical outcomes of 59 patients with bronchiolitis obliterans syndrome who were treated with belumosudil in 2 prospective trials, KD025-208 and KD025-213. The authors reported a best overall response rate (ORR) for lung chronic graft-versus-host disease (cGVHD) of 32% (partial response [PR]: 17%; complete response [CR]: 15%).
Since publication, the authors have found out that an additional 6 patients from the KD025-213 trial met the study criteria for having the following lung involvement at enrollment: the predicted forced expiratory volume in 1 second of ≤79% and clinician attribution of lung disease owing to cGVHD.
The baseline National Institutes of Health (NIH) lung score for these additional patients was 1 (n = 2) or 2 (n = 4). According to NIH response criteria, the best overall ORR for lung cGVHD in these additional patients was 83% (PR: 83%; CR: 0%). These response rates for these additional patients are in line with the initial report and do not significantly alter the article’s findings.
After addition of these 6 patients to the initial cohort of 59 patients, the best lung-specific ORR for all 65 patients is 37% (PR 23%; CR 14%). The ORRs according to baseline NIH GVHD lung score at enrollment are: lung score 1: 53%; lung score 2: 26%; and lung score 3: 0%.